Last reviewed · How we verify
NCT05348330
Mid-point to Pleura Transverse Process Block Versus Thoracic Intervertebral Foramen Block
NA trial testing Thoracic intervertebral foramen block in Pain, Acute in 100 participants. Completed in 28 November 2024.
31 October 2024
Quick facts
| Lead sponsor | San Salvatore Hospital of L'Aquila |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 4 December 2022 |
| Primary completion | 31 October 2024 |
| Estimated completion | 28 November 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Thoracic intervertebral foramen block
- Mid-point to pleura transverse process block
Conditions studied
- Pain, Acute — all drugs for Pain, Acute →
- Rib Fractures — all drugs for Rib Fractures →
- Polytrauma — all drugs for Polytrauma →
Sponsor
San Salvatore Hospital of L'Aquila
Who can join
Adults 18 to 75, any sex, with Pain, Acute or Rib Fractures. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The analgesic effect of continuous mid-point to pleura transverse process block compared to the analgesic effect of continuous thoracic intervertebral foramen block, in patients with multiple rib fractures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05348330
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Thoracic intervertebral foramen block
Trials testing the same drug.
- NCT05603442 — Thoracic Intervertebral Foramen Block · Phase 3 · completed
Other recruiting trials for Pain, Acute
Currently open trials in the same condition.
- NCT07249827 — A Randomized Comparison Between 0.67 mcg/kg, 1 mcg/kg, and 1.33 mcg/kg of Perineural Dexmedetomidine for Ultrasound-Guid · Phase 2 · recruiting
- NCT07053774 — Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain · Phase 2 · recruiting
- NCT07009951 — Impact of Virtual Reality in Cardiac Electrophysiology · recruiting
- NCT06960317 — Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements · NA · recruiting
- NCT06754657 — CORA-Q15: Continuous vs. Single-injection Interscalene Block on QoR-15 in Outpatient Rotator Cuff Surgery · Phase 4 · recruiting
Other San Salvatore Hospital of L'Aquila trials
Trials by the same sponsor.
- NCT07290959 — Indoor Daylight Photodynamic Therapy is an Effective, First-line Treatment for AK, But Its Feasibility is Limited by the · NA · completed
- NCT05603442 — Thoracic Intervertebral Foramen Block · Phase 3 · completed
- NCT04815304 — Clinical Features of COVID-19 Patients · completed
- NCT03941899 — The Analgesic Effect of QLB II After Robotic Prostatectomy. (QLB II: Quadratus Lomborum Block II Type) · NA · completed
- NCT03869710 — Analgesic Effects of Ultrasound-guided Dry-Needling Therapy for Neck and Head Pain · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05348330 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by San Salvatore Hospital of L'Aquila
- Last refreshed: 3 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05348330.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing